Electromed, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2020, filed August 25, 2020. The requested period is identified as “2019 Q4,” but the supplied filing is the fiscal 2020 annual report and includes fiscal 2019 comparisons.
Business Context
Electromed develops, manufactures and sells SmartVest high-frequency chest wall oscillation airway-clearance systems for patients with compromised pulmonary function. Revenue is generated primarily through direct-to-patient domestic home-care sales, with additional institutional, home-care distributor and international sales. The company operates as a single medical-equipment segment and is listed on the NYSE American under ELMD.
Key Financial Metrics
| Metric | Fiscal 2020 | Fiscal 2019 | Change |
|---|---|---|---|
| Net revenue | $32.47 million | $31.30 million | +3.7% |
| Gross profit | $25.20 million | $23.85 million | +5.7% |
| Gross margin | 77.6% | 76.2% | +140 basis points |
| Operating income | $5.12 million | $2.83 million | +80.9% |
| Net income | $4.16 million | $1.98 million | +110.1% |
| Diluted earnings per share | $0.47 | $0.23 | +104.3% |
| Cash flow from operations | $4.20 million | $2.59 million | +62.4% |
| Capital expenditures and patent costs | $0.98 million | $1.39 million | Decrease |
Revenue mix: Home care revenue was $29.32 million, institutional revenue was $2.00 million, new home-care distributor revenue was $430,000, and international revenue was $718,000. Approximately 94% of U.S. revenue came from home care and 6% from hospitals.
Balance sheet and liquidity: Cash was $10.48 million at June 30, 2020, compared with $7.81 million in 2019. Working capital was approximately $25.04 million. Total assets were $33.24 million and shareholders’ equity was $30.25 million. There was no outstanding principal balance under the credit facility, and the full $2.5 million borrowing capacity was available at year-end.
Debt and commitments: The company had no outstanding revolving borrowings and had paid off its approximately $1.10 million term loan in December 2018. The revolving facility expires December 18, 2020 if not renewed, bears interest at prime less 1%, and includes tangible-net-worth and other covenants. Operating lease liabilities totaled approximately $81,000.
Material Changes Versus Fiscal 2019
- Revenue increased 3.7%, led by institutional growth of 24.7% and the launch of home-care distributor sales. Home-care revenue increased only 1.3% because COVID-19 reduced referrals late in the year.
- Gross margin expanded to 77.6%, primarily due to payer mix and a higher average allowable reimbursement.
- SG&A declined 2.4% to $19.94 million, including lower payroll, compensation and travel costs, partially offset by higher professional, legal and recruiting expenses.
- Research and development expense increased to $1.05 million from $583,000 as the company invested in next-generation product enhancements.
- Net income benefited from $913,000 of CARES Act Provider Relief Fund income and an approximately $358,000 discrete tax benefit related to exercised non-qualified stock options. These items make the year-over-year earnings increase less representative of recurring operating performance.
- The company adopted ASC 842 lease accounting retrospectively. The reported effect on fiscal 2019 net income was an increase of approximately $11,000, with limited impact on operating results.
- Cash increased by $2.67 million, supported by operating cash flow and lower investing outlays, while financing cash flow included $628,000 of taxes paid on behalf of employees for net stock-option exercises.
Outlook, Commentary and Risks
Management’s fiscal 2021 priorities include increasing adult pulmonology and bronchiectasis referrals, improving sales productivity, expanding clinical evidence, enhancing patient and provider support, developing product features, and growing institutional market share. Management expects R&D spending as a percentage of sales to increase slightly.
COVID-19 restricted access to clinicians, reduced home-care referrals and postponed institutional orders during the fourth quarter of fiscal 2020. Referral levels were near prior-year levels as the fiscal year ended, but institutional demand remained pressured. Management expects the impact to lessen during fiscal 2021, while acknowledging that renewed outbreaks or restrictions could materially harm operations, cash flows and financial condition. Manufacturing furloughs and other cost-containment measures continued through July 2020 before full employment resumed.
Temporary CMS waivers reduced documentation and face-to-face requirements for certain Medicare respiratory-device claims during the public health emergency, then scheduled to expire in October 2020. The expiration or modification of these waivers could affect referrals and reimbursement.
Key risks include dependence on Medicare, Medicaid and private-payer reimbursement; changes in coverage or reimbursement rates; competition from Hill-Rom, Philips/RespirTech and International Biophysics; regulatory and FDA compliance; product liability and warranty obligations; supply-chain disruption; protection of intellectual property; international-market risks; and renewal of the revolving credit facility.
The company maintains lifetime warranties for qualifying U.S. and Canadian home-care patients and three-year warranties for most institutional and international sales. The warranty reserve was $740,000 at June 30, 2020. Management reported no material pending litigation and no off-balance-sheet arrangements.
Most Important Facts to Verify
- Whether the revolving credit facility was renewed after its December 18, 2020 expiration date and whether any covenant changes occurred.
- The sustainability of fiscal 2020 earnings excluding the $913,000 CARES Act benefit and approximately $358,000 discrete tax benefit.
- Post-pandemic trends in home-care referrals, institutional orders and home-care distributor revenue.
- Any changes to CMS waivers, Medicare reimbursement, payer mix or allowable amounts for HCPCS code E0483.
- Progress and spending related to next-generation products, SmartVest Connect and bronchiectasis clinical evidence.
- Compliance with the European Union Medical Device Regulation transition targeted for May 2021 and the expiration of a U.S. patent during fiscal 2021.